Targets › NOD2
2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Jul 2033.
Pattern recognition receptor (PRR) that detects bacterial peptidoglycan fragments and other danger signals and plays an important role in gastrointestinal immunity. Specifically activated by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan found in every bacterial peptidoglycan type. (UniProt, Q9HC29)
Open in Phaseline: the race on NOD2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Anna Raciborska | Mifamurtide Nucleotide-binding oligomerization domain-containing protein 2 other | NOD2 | Phase 2 | Osteosarcoma | Jul 2033 |
| UNICANCER | Mifamurtide Nucleotide-binding oligomerization domain-containing protein 2 other | NOD2 | Phase 2 | Osteosarcoma | Oct 2033 |
Osteosarcoma (2)
mixed (1), protein or peptide (1)
Anna Raciborska (1) UNICANCER (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.